Mark J. Foley, CEO at Revance Therapeutics, Inc. (RVNC), sold 140,894 shares at $34.55 ($4.9M) on 2023-05-15, disclosed to the SEC on 2023-05-16.
Open-market sale of $4.9M RVNC by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.55 | 70,447 | $2.4M | 50.0% |
| 2 | $34.55 | 70,447 | $2.4M | 50.0% |
| Total | $34.55 avg | 140,894 | $4.9M | 100% |
| Filing → |
| GKOS | SELL | 2024-02-26 | $847K | — | Filing → |
| RVNC | SELL | 2023-08-04 | $1.2M | — | Filing → |
| RVNC | SELL | 2023-07-05 | $1.3M | — | Filing → |